| Code | Description | Claims | Bene. Records | Total Paid |
|---|
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
220 |
219 |
$31K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
461 |
441 |
$27K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
83 |
73 |
$9K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
202 |
201 |
$6K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
130 |
130 |
$5K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
196 |
196 |
$5K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
81 |
80 |
$4K |
| S0302 |
Completed early periodic screening diagnosis and treatment (epsdt) service (list in addition to code for appropriate evaluation and management service) |
217 |
216 |
$2K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
154 |
152 |
$2K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
12 |
12 |
$994.32 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
41 |
40 |
$598.60 |
| 99173 |
|
27 |
27 |
$540.00 |
| 90461 |
|
14 |
14 |
$531.36 |
| 96127 |
|
45 |
42 |
$462.15 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
12 |
12 |
$173.40 |
| 81002 |
|
13 |
12 |
$39.91 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
12 |
12 |
$7.56 |